

Research on discovery of lead compounds to develop oral refractory cancer treatment targeting PTM(Post-translational modification) inhibition mechanism

INNOVO Therapeutics



ONCOLOGY	Lead
Product Type	Small molecule
Indication	AML (Acute Myeloid Leukemia)
Target	NMT (N-myristoyltransferase)
MoA(Mechanism of Action)	Induces tumor-cell death by inhibiting the N-myristoylation of proteins essential for tumor-cell growth and survival.
Competitiveness	<ul style="list-style-type: none"> - High binding affinity, driven by the compound's structural specificity. - Superior <i>in-vitro</i> activity versus the in-class comparator PCLX-001. - Excellent efficacy across AML cell lines harboring diverse genetic mutations.
Development Stage	Lead
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.